News focus: Amgen suffers UK patent defeat

In a landmark decision, the House of Lords has invalidated Amgen's key patent for erythropoietin. James Nurton examines the impact of the ruling
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: